|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2450 CAD | +28.95% |
|
+8.89% | +48.48% |
| 11-20 | Vext Science, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
| 11-20 | Vext Science, Inc., Q3 2025 Earnings Call, Nov 20, 2025 |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Revenues | 25.19M | 37.24M | 35.41M | 34.81M | 36M | |||
Total Revenues | 25.19M | 37.24M | 35.41M | 34.81M | 36M | |||
Cost of Goods Sold, Total | 14.44M | 18.82M | 12.31M | 22.77M | 27.02M | |||
Gross Profit | 10.75M | 18.42M | 23.1M | 12.04M | 8.98M | |||
Selling General & Admin Expenses, Total | 4.22M | 4.82M | 8.37M | 13.46M | 10.73M | |||
Stock-Based Compensation (IS) | 880K | 950K | 1.45M | 385K | 696K | |||
R&D Expenses | 159K | 150K | - | - | - | |||
Depreciation & Amortization - (IS) | - | - | 664K | 1.19M | 396K | |||
Amortization of Goodwill and Intangible Assets - (IS) | 2.14M | 3.29M | 3.33M | 4.85M | 8.34M | |||
Other Operating Expenses | 126K | 1.22M | 12.37K | -19K | 374K | |||
Other Operating Expenses, Total | 7.52M | 10.43M | 13.83M | 19.86M | 20.53M | |||
Operating Income | 3.23M | 7.99M | 9.27M | -7.82M | -11.55M | |||
Interest Expense, Total | -27.62K | -35.49K | -2.04M | -3.81M | -3.55M | |||
Interest And Investment Income | 379K | 739K | 112K | 157K | 220K | |||
Net Interest Expenses | 351K | 704K | -1.93M | -3.65M | -3.33M | |||
Income (Loss) On Equity Invest. | -521K | -540K | -466K | 1.93M | -3.65M | |||
Currency Exchange Gains (Loss) | 328K | -10.73K | 1.19K | -5.37K | 619 | |||
Other Non Operating Income (Expenses) | -592K | -899K | 1 | - | -1.79M | |||
EBT, Excl. Unusual Items | 2.8M | 7.24M | 6.88M | -9.55M | -20.32M | |||
Merger & Related Restructuring Charges | - | - | - | - | - | |||
Gain (Loss) On Sale Of Investments | - | -425K | - | - | - | |||
Gain (Loss) On Sale Of Assets | -161K | 3.2K | 20.4K | -811K | -147K | |||
Other Unusual Items | - | - | -200K | 13.72M | -651K | |||
EBT, Incl. Unusual Items | 2.64M | 6.82M | 6.7M | 3.36M | -21.12M | |||
Income Tax Expense | 514K | 1.83M | -4.22M | -1.04M | 1.31M | |||
Earnings From Continuing Operations | 2.13M | 4.99M | 10.92M | 4.4M | -22.44M | |||
Net Income to Company | 2.13M | 4.99M | 10.92M | 4.4M | -22.44M | |||
Net Income - (IS) | 2.13M | 4.99M | 10.92M | 4.4M | -22.44M | |||
Net Income to Common Incl Extra Items | 2.13M | 4.99M | 10.92M | 4.4M | -22.44M | |||
Net Income to Common Excl. Extra Items | 2.13M | 4.99M | 10.92M | 4.4M | -22.44M | |||
Per Share Items | ||||||||
Net EPS - Basic | 0.02 | 0.04 | 0.08 | 0.03 | -0.09 | |||
Basic EPS - Continuing Operations | 0.02 | 0.04 | 0.08 | 0.03 | -0.09 | |||
Basic Weighted Average Shares Outstanding | 92.77M | 137M | 139M | 164M | 241M | |||
Net EPS - Diluted | 0.02 | 0.03 | 0.08 | 0.03 | -0.09 | |||
Diluted EPS - Continuing Operations | 0.02 | 0.03 | 0.08 | 0.03 | -0.09 | |||
Diluted Weighted Average Shares Outstanding | 93.53M | 146M | 140M | 165M | 241M | |||
Normalized Basic EPS | 0.02 | 0.03 | 0.03 | -0.04 | -0.05 | |||
Normalized Diluted EPS | 0.02 | 0.03 | 0.03 | -0.04 | -0.05 | |||
Supplemental Items | ||||||||
EBITDA | 5.34M | 11.25M | 15.52M | 1.54M | 2.84M | |||
EBITA | 3.85M | 8.82M | 12.42M | -3.2M | -3.99M | |||
EBIT | 3.23M | 7.99M | 9.27M | -7.82M | -11.55M | |||
EBITDAR | 5.44M | 11.56M | - | - | - | |||
Total Revenues (As Reported) | 25.19M | 37.24M | - | - | - | |||
Effective Tax Rate - (Ratio) | 19.48 | 26.88 | -63.03 | -30.8 | -6.22 | |||
Current Foreign Taxes | - | - | - | - | - | |||
Total Current Taxes | - | - | 2.76M | -800K | 2.31M | |||
Deferred Foreign Taxes | - | - | - | - | - | |||
Total Deferred Taxes | 514K | 1.83M | -6.98M | -235K | -992K | |||
Normalized Net Income | 1.75M | 4.53M | 4.3M | -5.97M | -12.7M | |||
Interest on Long-Term Debt | 121K | 63.62K | 119K | 209K | 413K | |||
Supplemental Operating Expense Items | ||||||||
Advertising Expense | 444K | 487K | - | - | - | |||
Selling and Marketing Expenses | 444K | 487K | - | - | - | |||
General and Administrative Expenses | 1.91M | 2.46M | 4.9M | 8.33M | 5.53M | |||
Research And Development Expense From Footnotes | 159K | 150K | - | - | - | |||
Net Rental Expense, Total | 98.52K | 316K | - | - | - | |||
Imputed Operating Lease Interest Expense | 2.32K | 7.02K | - | - | - | |||
Imputed Operating Lease Depreciation | 96.2K | 309K | - | - | - | |||
Maintenance & Repair Expenses, Total | 445K | 265K | - | - | - | |||
Stock-Based Comp., Other (Total) | 880K | 950K | 1.45M | 385K | 696K | |||
Total Stock-Based Compensation | 880K | 950K | 1.45M | 385K | 696K |
- Stock Market
- Equities
- VEXT Stock
- Financials Vext Science, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















